PE20190661A1 - Preparacion de derivados del factor xa - Google Patents
Preparacion de derivados del factor xaInfo
- Publication number
- PE20190661A1 PE20190661A1 PE2018003241A PE2018003241A PE20190661A1 PE 20190661 A1 PE20190661 A1 PE 20190661A1 PE 2018003241 A PE2018003241 A PE 2018003241A PE 2018003241 A PE2018003241 A PE 2018003241A PE 20190661 A1 PE20190661 A1 PE 20190661A1
- Authority
- PE
- Peru
- Prior art keywords
- sample
- polypeptide
- acid sequence
- eluting
- loading
- Prior art date
Links
- 108010074860 Factor Xa Proteins 0.000 title abstract 2
- 238000002360 preparation method Methods 0.000 title abstract 2
- 239000000523 sample Substances 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 239000012149 elution buffer Substances 0.000 abstract 3
- 108091033319 polynucleotide Proteins 0.000 abstract 3
- 102000040430 polynucleotide Human genes 0.000 abstract 3
- 239000002157 polynucleotide Substances 0.000 abstract 3
- 108091028043 Nucleic acid sequence Proteins 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000007523 nucleic acids Chemical group 0.000 abstract 2
- 101710162629 Trypsin inhibitor Proteins 0.000 abstract 1
- 229940122618 Trypsin inhibitor Drugs 0.000 abstract 1
- 238000010276 construction Methods 0.000 abstract 1
- 239000003599 detergent Substances 0.000 abstract 1
- 230000002209 hydrophobic effect Effects 0.000 abstract 1
- 229910017053 inorganic salt Inorganic materials 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 238000005342 ion exchange Methods 0.000 abstract 1
- 239000003960 organic solvent Substances 0.000 abstract 1
- 239000012521 purified sample Substances 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- 239000002753 trypsin inhibitor Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6432—Coagulation factor Xa (3.4.21.6)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/18—Ion-exchange chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Detergent Compositions (AREA)
Abstract
Referido a la preparacion de derivados modificado de la proteina del Factor Xa, para preparar un producto de polipeptido expresado a partir de una construccion de polinucleotidos, comprende la secuencia de acido nucleico de la SEQ ID NO: 7, o una secuencia de acido nucleico que codifica una secuencia de aminoacidos que tiene al menos 90% de identidad de secuencia con la secuencia de aminoacidos codificada por la SEQ ID NO:7, en la que comprende: agregar un detergente a una muestra que contiene una construccion de polinucleotidos expresado a partir de la construccion de polinucleotidos; cargar la muestra en un cromatografo por afinidad basado en el inhibidor la tripsina de soja (STI) y eluir el polipeptido con un primer amortiguador de elucion para generar una primera muestra eluida, donde la muestra cargada no contiene un solvente organico; cargar la primera muestra eluida en un cromatografo de modo mixto y de intercambio de iones y eluir el polipeptido con un segundo amortiguador de elucion que comprende al menos 1 M de una sal inorganica para generar una segunda muestra eluida; y cargar la segunda muestra eluida en un cromatografo de interaccion hidrofobica y eluir el polipeptido con un tercer amortiguador de elucion que comprende cloruro de sodio al menos 2mM, preparando de este modo una muestra purificada que comprende el producto de polipeptido.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662351841P | 2016-06-17 | 2016-06-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20190661A1 true PE20190661A1 (es) | 2019-05-08 |
Family
ID=60663351
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2018003241A PE20190661A1 (es) | 2016-06-17 | 2017-06-19 | Preparacion de derivados del factor xa |
Country Status (23)
Country | Link |
---|---|
US (4) | US10604748B2 (es) |
EP (2) | EP3926044A1 (es) |
JP (3) | JP6959268B2 (es) |
KR (1) | KR102373215B1 (es) |
CN (2) | CN116425860A (es) |
AU (2) | AU2017283720B2 (es) |
BR (1) | BR112018075964A2 (es) |
CA (1) | CA3027457A1 (es) |
CL (2) | CL2018003654A1 (es) |
CO (1) | CO2019000120A2 (es) |
DK (1) | DK3472314T3 (es) |
EA (1) | EA037815B1 (es) |
ES (1) | ES2875538T3 (es) |
HU (1) | HUE054597T2 (es) |
IL (1) | IL263591B2 (es) |
MX (1) | MX2018015873A (es) |
PE (1) | PE20190661A1 (es) |
PH (1) | PH12018502614A1 (es) |
PL (1) | PL3472314T3 (es) |
PT (1) | PT3472314T (es) |
SG (1) | SG11201810915QA (es) |
SI (1) | SI3472314T1 (es) |
WO (1) | WO2017219034A2 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010117729A1 (en) * | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
SG11201505627RA (en) * | 2013-01-24 | 2015-08-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
KR102373215B1 (ko) * | 2016-06-17 | 2022-03-10 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Xa 유도체의 제조 |
EP3810187A4 (en) * | 2018-06-19 | 2022-08-31 | Alexion Pharmaceuticals, Inc. | ANTIDOTES FOR FACTOR XA INHIBITORS |
KR102337683B1 (ko) * | 2018-09-21 | 2021-12-13 | 주식회사 녹십자 | 고효율 항-tfpi 항체 조성물 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5189019A (en) * | 1990-04-23 | 1993-02-23 | Merck & Co., Inc. | Antistasin derived anticoagulant protein |
US5589571A (en) * | 1994-10-28 | 1996-12-31 | Cor Therapeutics, Inc. | Process for production of inhibited forms of activated blood factors |
JPH1066572A (ja) * | 1996-08-29 | 1998-03-10 | Showa Sangyo Co Ltd | 高純度の大豆トリプシンインヒビターの製造方法 |
ATE311366T1 (de) | 2000-02-29 | 2005-12-15 | Millennium Pharm Inc | Benzamide und ähnliche inhibitoren vom faktor xa |
NZ567992A (en) | 2005-11-08 | 2011-05-27 | Millennium Pharm Inc | Pharmaceutical salts and polymorphs of N-(5-chloro-2-pyridinyl)-2-[[4-[(dimethylamino)iminomethyl]benzoyl]amino]-5-methoxy-benzamide, a factor Xa inhibitor |
HUE052423T2 (hu) | 2007-09-28 | 2021-04-28 | Alexion Pharma Inc | Az XA faktor inhibitorok antidótumai és ezek alkalmazási módszerei |
MX2011004907A (es) | 2008-11-14 | 2011-07-29 | Portola Pharm Inc | Antidotos para inhibidores del factor xa y metodos para el uso de los mismos en combinacion con agentes de coagulacion de sangre. |
WO2010117729A1 (en) | 2009-03-30 | 2010-10-14 | Portola Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
JP6163304B2 (ja) | 2009-07-15 | 2017-07-12 | ポートラ ファーマシューティカルズ, インコーポレイテッド | 第Xa因子インヒビターの解毒剤の単位用量処方物およびその使用方法 |
SG11201408028YA (en) * | 2012-06-14 | 2015-01-29 | Portola Pharm Inc | METHOD FOR PURIFICATION OF RECOMBINANT FACTOR Xa DERIVATIVES |
US20140346397A1 (en) * | 2012-12-27 | 2014-11-27 | Portola Pharmaceuticals, Inc. | Compounds and methods for purification of serine proteases |
SG11201505627RA (en) | 2013-01-24 | 2015-08-28 | Portola Pharm Inc | INHIBITION OF TISSUE FACTOR PATHWAY INHIBITOR WITH FACTOR Xa DERIVATIVES |
CN105579468A (zh) * | 2013-09-24 | 2016-05-11 | 辉瑞大药厂 | 包含重组人凝血因子Xa蛋白的异质性群体的组合物 |
CN107073082B (zh) * | 2014-08-20 | 2021-04-30 | 博尔托拉制药公司 | Xa因子解毒剂的冻干制剂 |
KR102373215B1 (ko) * | 2016-06-17 | 2022-03-10 | 포톨라 파마슈티컬스, 인코포레이티드 | 인자 Xa 유도체의 제조 |
-
2017
- 2017-06-19 KR KR1020197000840A patent/KR102373215B1/ko active IP Right Grant
- 2017-06-19 PE PE2018003241A patent/PE20190661A1/es unknown
- 2017-06-19 EP EP21164923.1A patent/EP3926044A1/en active Pending
- 2017-06-19 JP JP2018565888A patent/JP6959268B2/ja active Active
- 2017-06-19 HU HUE17814267A patent/HUE054597T2/hu unknown
- 2017-06-19 EA EA201990052A patent/EA037815B1/ru not_active IP Right Cessation
- 2017-06-19 EP EP17814267.5A patent/EP3472314B1/en active Active
- 2017-06-19 AU AU2017283720A patent/AU2017283720B2/en active Active
- 2017-06-19 PT PT178142675T patent/PT3472314T/pt unknown
- 2017-06-19 SG SG11201810915QA patent/SG11201810915QA/en unknown
- 2017-06-19 DK DK17814267.5T patent/DK3472314T3/da active
- 2017-06-19 CN CN202310427500.2A patent/CN116425860A/zh active Pending
- 2017-06-19 PL PL17814267T patent/PL3472314T3/pl unknown
- 2017-06-19 US US15/626,813 patent/US10604748B2/en active Active
- 2017-06-19 CA CA3027457A patent/CA3027457A1/en active Pending
- 2017-06-19 CN CN201780041530.2A patent/CN110167575B/zh active Active
- 2017-06-19 SI SI201730865T patent/SI3472314T1/sl unknown
- 2017-06-19 IL IL263591A patent/IL263591B2/en unknown
- 2017-06-19 BR BR112018075964-3A patent/BR112018075964A2/pt unknown
- 2017-06-19 WO PCT/US2017/038169 patent/WO2017219034A2/en unknown
- 2017-06-19 ES ES17814267T patent/ES2875538T3/es active Active
- 2017-06-19 MX MX2018015873A patent/MX2018015873A/es unknown
-
2018
- 2018-12-11 PH PH12018502614A patent/PH12018502614A1/en unknown
- 2018-12-17 CL CL2018003654A patent/CL2018003654A1/es unknown
-
2019
- 2019-01-09 CO CONC2019/0000120A patent/CO2019000120A2/es unknown
-
2020
- 2020-01-10 US US16/740,001 patent/US10954504B2/en active Active
- 2020-06-25 CL CL2020001733A patent/CL2020001733A1/es unknown
-
2021
- 2021-03-09 US US17/196,172 patent/US11845966B2/en active Active
- 2021-10-07 JP JP2021165271A patent/JP7273918B2/ja active Active
-
2023
- 2023-02-14 AU AU2023200825A patent/AU2023200825A1/en active Pending
- 2023-04-28 JP JP2023074627A patent/JP2023086970A/ja active Pending
- 2023-11-08 US US18/505,022 patent/US20240076642A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20190661A1 (es) | Preparacion de derivados del factor xa | |
BR112020024863A2 (pt) | Nucleases guiadas por rna, fragmentos ativos e variantes das mesmas e métodos de uso | |
PE20171111A1 (es) | Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso | |
EP3712165A3 (en) | Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers | |
WO2017024317A3 (en) | Methods to induce targeted protein degradation through bifunctional molecules | |
PH12020550240A1 (en) | D-domain containing polypeptides and uses thereof | |
BR112017015567A2 (pt) | proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica | |
AR108442A1 (es) | Proteínas de fusión gdf15 y usos de estas | |
BR112017026523A2 (pt) | vetor recombinante, adenovírus recombinante, composição, uso de um vetor recombinante, de um adenovírus recombinante ou de uma composição, método para induzir uma resposta imune em um indivíduo, e, polinucleotídeo isolado. | |
MX2019000898A (es) | Amortiguador de lavado de cromatografia de afinidad. | |
WO2015051199A3 (en) | Modified pseudomonas exotoxin a | |
CL2019003404A1 (es) | Péptido asociados a tumor (tumap) aislado; ácido nucleico; vector de expresión; célula huésped recombinante que comprendes el péptido; método para producir el péptido; uso para preparar un medicamento útil rara tratar el cáncer; kit farmacéutico.(divisional solicitud 201702407) | |
EA201590545A1 (ru) | Полипептиды, содержащие fc с измененным гликозилированием и сниженной эффекторной функцией | |
PE20161442A1 (es) | Proteinas quimericas tipo fosfatasa alcalina | |
HRP20220531T1 (hr) | Varijabilni fragmenti antitijela koji se umeću i modificirane a1-a2 domene nkg2d liganda | |
MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
BR112017018365A2 (pt) | uso de lavagens alcalinas durante cromatografia para remoção de impurezas | |
EA201691011A1 (ru) | Последовательность модифицированного эндолизина el188 | |
EP3543335A3 (en) | Soluble intein fusion proteins and methods for purifying biomolecules | |
BR112017020308A2 (pt) | udp-glicosiltransferases | |
EA202190240A1 (ru) | Варианты рекомбинантного белка | |
WO2016130628A8 (en) | Griffithsin mutants | |
MX2021005555A (es) | Vectores vegetales, composiciones y usos relacionados con los mismos. | |
BR112017026142A2 (pt) | composições e métodos para tratar doença sprue celíaca | |
MX2017010359A (es) | Cadena alfa del receptor de inmunoglobulina e (ige) de alta afinidad de fusion de fragmento cristalizable (fc). |